| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1392594 | European Journal of Medicinal Chemistry | 2014 | 10 Pages |
•Nineteen novel biotin–squamocin/bullatacin conjugates have been synthesized.•They are designed for targeted delivery to biotin receptor (+) tumor cells.•Activity of 16 against biotin receptor (+) tumor cells is significantly improved.•The biotinylation site and the presence of linker affect the activity.
Nineteen biotinylated squamocin/bullatacin derivatives have been synthesized for targeted delivery to biotin receptor overexpressed tumor cells. Most biotinylated squamocin and bullatacin derivatives show similar in vitro cytotoxicity against the biotin receptor non-overexpressed L1210 cells as squamocin and bullatacin, respectively, while against biotin receptor overexpressed 4T1 and P815 tumor cells, several derivatives show significantly higher potency and better selectivity. Among all the synthesized compounds, 15,28-di-O-(6-biotinylamidohexanoyl)squamocin (16) is the most potent, which is 10 and 26 times more active than squamocin against 4T1 and P815 cells, respectively. Compound 16 also appears to be six and fifteen times more selective than squamocin towards 4T1 and P815 cells, respectively, against L1210 cells. The structure activity relationship analysis has revealed that the preferred site for biotinylation is different for squamocin and bullatacin, and it also depends on whether a linking spacer is present.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
